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Abstract
Epstein-Barr virus (EBV), a lymphomagenic human herpesvirus, colonises the host through polyclonal B cell-growth-
transforming infections yet establishes persistence only in IgD
+ CD27
+ non-switched memory (NSM) and IgD
2 CD27
+
switched memory (SM) B cells, not in IgD
+ CD27
2 naı ¨ve (N) cells. How this selectivity is achieved remains poorly understood.
Here we show that purified N, NSM and SM cell preparations are equally transformable in vitro to lymphoblastoid cells lines
(LCLs) that, despite upregulating the activation-induced cytidine deaminase (AID) enzyme necessary for Ig isotype switching
and Ig gene hypermutation, still retain the surface Ig phenotype of their parental cells. However, both N- and NSM-derived
lines remain inducible to Ig isotype switching by surrogate T cell signals. More importantly, IgH gene analysis of N cell
infections revealed two features quite distinct from parallel mitogen-activated cultures. Firstly, following 4 weeks of EBV-
driven polyclonal proliferation, individual clonotypes then become increasingly dominant; secondly, in around 35% cases
these clonotypes carry Ig gene mutations which both resemble AID products and, when analysed in prospectively-
harvested cultures, appear to have arisen by sequence diversification in vitro. Thus EBV infection per se can drive at least
some naı ¨ve B cells to acquire Ig memory genotypes; furthermore, such cells are often favoured during an LCL’s evolution to
monoclonality. Extrapolating to viral infections in vivo, these findings could help to explain how EBV-infected cells become
restricted to memory B cell subsets and why EBV-driven lymphoproliferative lesions, in primary infection and/or
immunocompromised settings, so frequently involve clones with memory genotypes.
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Introduction
Epstein-Barr virus (EBV), an orally transmitted herpesvirus
widespread in human populations, first replicates in a permissive
cell type in the oropharynx and then colonises the B cell system
through a growth-transforming infection that drives the clonal
expansion of latently-infected cells [1–3]. This growth transfor-
mation can be studied in vitro where infection of resting B cells
occurs via CD21 receptor-mediated virus entry and leads to the
outgrowth of permanent lymphoblastoid cell lines (LCLs)
expressing all eight EBV latent cycle proteins (six nuclear antigens
EBNAs 1, 2, 3A, 3B, 3C and –LP, and two latent membrane
proteins LMPs 1 and 2) [3]. Cells displaying these same markers of
viral transformation are present in the tonsillar lymphoid tissues of
infectious mononucleosis (IM) patients undergoing primary EBV
infection [4,5]. Already, however, there is heterogeneity within
these expanding B cell clones in IM tonsils [5,6], with some cells
apparently down-regulating viral antigen expression and switching
out of cell cycle, thereby establishing a latent reservoir that can
evade detection by the host T cell response. A key finding was that
the cells constituting this reservoir, whether in the blood of
convalescent IM patients or of long-term EBV carriers, lie within
the IgD
2 CD27
+ memory B cell subset and not in IgD
+ CD27
2
naı ¨ve cells [7–9]. Furthermore, in IM cases where infected cell
numbers were sufficient to allow single cell analysis, these cells
carried somatically-mutated immunoglobulin (Ig) gene sequences
typical of antigen-experienced memory cells [9], as do many of the
EBV-driven lymphoproliferative disease lesions that arise in
immunocompromised patients where T cell control is relaxed
[10–14].
The physiologic process of memory selection involves IgM
+
IgD
+ CD27
2 naı ¨ve B cells encountering cognate antigen in
lymphoid tissues and, with antigen-specific T cell help, prolifer-
ating to form germinal centres (GCs). Here Ig variable gene
sequences are subject to successive rounds of somatic hypermuta-
tion (SHM) to generate intra-clonal diversity before being re-
expressed, usually in isotype-switched forms [15]. Both SHM and
isotype-switching are critically dependent upon activation-induced
PLoS Pathogens | www.plospathogens.org 1 May 2012 | Volume 8 | Issue 5 | e1002697cytidine deaminase, AID [16,17], but are nevertheless distinct
reactions that can take place independently of one another
[18,19]. The small fraction of GC progeny cells with improved
affinity for antigen are then specifically selected by T cell-derived
survival signals, emerging as IgD
2 CD27
+ memory B cells; the
great majority of these are also IgM
2 and have switched isotype to
IgG or IgA, (‘‘switched memory’’ cells) [20] . Given this
understanding of the physiology of memory cell selection, different
views have emerged as to how EBV might selectively colonise the
IgD
2 CD27
+ memory cell pool. One view is that the virus first
infects naı ¨ve cells in vivo and, through mimicking the activation
signals normally induced by cognate antigen, drives these cells to
initiate a GC reaction; the virus-infected clonal descendents of that
reaction thus acquire both the genotype and phenotype of
memory cells via the natural process of GC transit, albeit with
virus-coded LMPs 1 and 2 substituting for affinity-based survival
signals [1]. A second view, based mainly on the analysis of EBV-
infected B cell clones within IM tonsillar tissues, is that memory B
cells are preferentially infected, or possibly have a proliferative/
survival advantage during the phase of virus-driven B cell
expansion, and that their progeny subsequently re-assume
memory characteristics with no requirement for GC transit [2].
An added complication to this debate is the more recent finding
[21] that EBV is harboured not just in the conventional IgD
2
CD27
+ memory pool of healthy virus carriers but also at lower
levels in a second distinct memory population comprising IgD
+
CD27
+ ‘‘non-switched memory’’ cells [20,22], that had hitherto
been largely ignored in EBV studies. Although such cells do carry
somatically mutated Ig genes, opinion is divided as to whether the
IgD
+ CD27
+ subset arises ontogenetically and is entirely
independent of GC activity (as their presence in certain GC-null
immune-deficiency states would imply [23,24]) or is populated at
least in part by the products of abortive/incomplete GC reactions
involving Ig gene mutation without isotype switching [20,25–28].
EBV’s ability to colonise this subset in healthy individuals can
therefore be explained in different ways depending upon one’s
view of non-switched memory B cell origins. Interestingly
however, in T cell-deficiency states where GC development is
blocked and there are no conventional switched memory B cells,
EBV is sequestered in the tiny population of Ig gene-mutated,
non-switched memory cells that exists in such patients rather than
in the numerically dominant naive population [29,30]. The
chances of incoming virus selectively targeting such a small
population by direct infection seems remote, again raising the
possibility that, in naive B cells, EBV infection per se may be able to
impose a memory genotype and/or phenotype on these cells
without recourse to GC signals.
Given these uncertainties, it is surprising that little attention has
been given to studying naı ¨ve, non-switched-memory and switched-
memory (here designated N, NSM and SM respectively) B cell
subsets as targets of EBV infection in vitro. Specifically, can naı ¨ve
cells acquire aspects of the memory cell Ig phenotype or genotype
as a result of virus transformation? Here we show that EBV
infection per se does not alter the Ig phenotype of naive cells,
although such infected cells remain susceptible to Ig class switch
induction by surrogate T cell signals. However, we did find
evidence for Ig gene mutation among naive B cell transformants;
thus, both under limiting dilution and bulk culture conditions,
selection for successful LCL outgrowth from naı ¨ve B cell infections
frequently involved clones with mutated Ig genotypes that appear
to have arisen through virus-induced SHM in vitro.
Results
Characteristics of purified B cell subsets
Circulating B cells, typically representing 4–8% of adult PBMC
populations, were isolated by CD19 bead selection to purities
consistently .98%, as shown by staining for the pan-B cell marker
CD20 (Figure 1A). Such preparations were co-stained with
fluorochrome-labelled Abs to IgD and CD27 in order to identify
the N (IgD
+ CD27
2), NSM (IgD
+CD27
+) and SM (IgD
2 CD27
+)
B cell subsets. Naı ¨ve B cells always represented the major subset,
accounting for 60–70% of total B cell numbers, with the other two
subsets each constituting between 8–25%. All three subsets were
isolated to high purity by FACS sorting. Figure 1B illustrates the
sort gates used and Figure 1C shows the results of re-analysing IgD
and CD27 staining on the sorted populations. By these criteria,
purity was always .99% for N, .96% for NSM and .98% for
SM cell preparations. IgH sequence analysis further confirmed the
purity of these sorts. Thus, combining results from naive cell sorts
from 12 different individuals, 188 of 195 IgH sequences amplified
from the N cell population were deemed to be non-mutated (i.e.
less than 2 nucleotide changes from germline). In six of the above
experiments, IgH sequencing was also extended to include the
other subsets; as expected, the great majority of sequences
amplified from the NSM and SM cell populations (33/37 and
64/66 respectively) were clearly mutated (Figure 1D).
Infectability of purified B cell subsets
Expression of the CD21 receptor and levels of virus binding
were determined for the above B cell subsets from 4 successive
PBMC samples. Cell surface staining with a mAb to the EBV
receptor CD21 reproducibly showed that N, NSM and SM cells
express CD21 at similar levels (Figure 2A). Likewise these cells all
bound virus to similar amounts, as measured by exposure to a
standard virus dose at 4uC to prevent internalisation of the virus,
followed by extensive washing and quantitation of EBV genome
copies bound per cell by quantitative PCR (data not shown). We
then assayed matched N, NSM and SM preparations for
transformability using two different experimental designs. In one
set of experiments, N, NSM and SM cells were exposed to a
standard virus dose (50moi) before being seeded at a range of cell
Author Summary
Epstein-Barr virus (EBV), a growth-transforming virus linked
to several B cell lymphomas in man, is usually carried as an
asymptomatic latent infection in B lymphocytes. Such virus
carriage selectively involves memory, but not naive, B cells.
How this selectivity is achieved is poorly understood since
we find that naive and memory cell types are equally
susceptible to infection and growth transformation to
lymphoblastoid cell lines in vitro. Here we ask if EBV-
transformation of purified naı ¨ve B cells can induce key
features of memory cells, namely immunoglobulin (Ig)
class switching and Ig gene mutation. We find that EBV
does not induce Ig class switching (though the infected
cells remain responsive to exogenous switch signals) but
can induce Ig gene mutation. Thus, within 4 weeks of
infecting naive B cell preparations, one can often detect
cells carrying Ig mutations which appear to have arisen by
somatic hypermutation in vitro. Furthermore, in many
cases such cells become dominant during clonal evolution
of the emergent EBV-transformed cell line. Overall these
findings suggest a possible explanation as to why EBV is
selectively found in memory B cell populations in vivo and
why EBV-positive lymphoproliferative lesions/lymphomas
so frequently involve clones with mutated Ig genotypes.
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N and NSM cells were exposed to a range of virus dilutions before
seeding into a 96-well plate at a standard cell number. In both
cases, end points in the transformation assay were scored after 6
weeks by microscopic inspection of cultures for characteristic foci
of EBV-transformed cells. Typical results from such experiments
are shown in Figures 2B and 2C, and are expressed as the
percentage of replicate wells scoring positive at the limiting cell
seeding or limiting virus dose. Whilst absolute values for
transformation efficiency varied between experiments, for any
one individual donor the three B cell subsets always gave very
similar yields of transformed cultures. Thereafter, cultures scoring
positive on plates set up under limiting conditions were first split
into duplicate wells and, where possible, further expanded over the
following 3–6 weeks to yield a limiting dilution (LD)-LCL for
analysis. Note that only a proportion of the wells transformed
under limiting conditions could be successfully expanded in this
way; overall, however, that proportion was not greatly different
comparing cultures derived from N (34%), NSM (30%) and SM
(24%) cell infections. We therefore conclude that the N, NSM and
SM subsets from peripheral blood are equally susceptible to EBV
infection and transformation in vitro.
Ig phenotype of EBV-transformed B cells of N-, NSM- and
SM origin
In several transformation experiments, we also set up LCLs
under non-limiting conditions by infecting 2610
6 N, NSM and
SM B cell preparations with EBV at 50moi and then culturing
these cells in bulk, with subsequent expansion to bulk LCLs. To
investigate whether EBV induced transformation altered Ig isotype
expression in the resultant lines, we first performed RT-PCR
analysis of IgH transcripts using isotype-specific primer combina-
tions. Figure 3A shows typical results obtained, using reference B
cell lines of known isotype restriction and the Ig-negative Jurkat T
cell line as internal controls. Bulk lines derived from the N and
NSM cell subsets were consistently positive for IgM transcripts and
weakly positive for IgD but negative for the other isotypes. By
Figure 1. Sorting and purity of B cell subsets. (A) Isolation of
CD20
+ B cells from peripheral blood. (B) Two colour FACS analysis of B
cells stained with CD27 and IgD mAbs to identify IgD
+ CD27
2 naı ¨ve (N),
IgD
+ CD27
+ non-switched memory (NSM) and IgD
2 CD27
+ switched
memory (SM) B cell populations. (C) Reanalysis to show purity of
isolated N, NSM and SM B cell preparations. The figures in each panel
indicate the purity of each isolated population D. Validation of cell
purity by IgH analysis of sorted B cell subsets. 188 of 195 amplified IgH
sequences obtained from 12 independent naive B cell preparations
were classified as germline (0–2 mutations, open bars); by contrast, 33
of 37 IgH sequences from 3 independent NSM B cell preparations, and
64 of 66 IgH sequences from 6 SM B cell preparations were scored as
mutated (shaded bars).
doi:10.1371/journal.ppat.1002697.g001
Figure 2. Transformation efficiency of B cell subsets. (A) FACS
analysis to measure surface CD21 expression on N (dotted line), NSM
(thin line) and SM (thick line) B cell subsets. Staining with isotype
control reagent is shown by shading. (B) Comparison of transformation
efficiencies of N, NSM and SM B cell preparations in limiting dilution
cultures. Cells were exposed to EBV at 50 moi (EBV genomes per cell) for
3 h, washed and then plated at 500 cells per well into 96 replicate wells
of a 96 well plate containing irradiated fibroblast feeder cells. The
numbers of wells containing growth transformed foci were scored after
6 weeks. Results are shown from two representative donors. (C)
Comparison of transformation efficiencies of N and NSM B cell
preparations at a range of virus concentrations. Cells were exposed to
EBV at the indicated moi for 3 h, washed and plated at 1000 cells per
well into replicate wells of a 96 well plate. The numbers of wells
showing transformation were scored after 6 weeks. Results are shown
from two representative donors.
doi:10.1371/journal.ppat.1002697.g002
EBV Infection of Naive B Cells In Vitro
PLoS Pathogens | www.plospathogens.org 3 May 2012 | Volume 8 | Issue 5 | e1002697contrast, bulk lines of SM cell origin expressed IgG and IgA
transcripts, often accompanied by a weak signal for IgM but never
for IgD; note that the weak IgM signal accords with the fact a very
small proportion of cells within sorted IgD
2 CD27
+ memory
populations are so-called ‘‘IgM-only’’ cells with an IgM
+ IgD
2
CD27
+ phenotype [25].
The clear inference from these transcriptional data, that viral
transformation had not induced detectable class switching, was
strongly supported by the results of staining with mAbs specific for
IgM, IgD, IgG and IgA heavy chains. Figure 3B shows typical
results where both the N-derived and NSM-derived bulk LCLs
retained an IgM
+ IgD
+ phenotype, whereas the SM-derived LCL
was dominated by IgG
+ and IgA
+ cells. Note also that, as others
have reported [31], EBV transformation induces N cells to express
CD27 such that all three groups of LCLs shared a CD27
+
phenotype (data not shown). Table 1 summarises the Ig isotype
data both from bulk LCLs of N, NSM or SM origin generated as
above, and from the LD-LCLs expanded from cultures of all 3 B
cell subsets as described earlier. Again, all N- and NSM-derived
cell lines from bulk and LD cultures were IgM
+ IgD
+; by contrast
the SM-derived bulk lines were predominantly mixtures of IgG
+
and IgA
+ cells, sometimes with a small IgM+ component, whereas
SM-derived LD cultures were either only IgG
+, only IgA
+ or
mixtures of both.
Responsiveness of EBV-transformed B cells to isotype-
switch signals
We then asked whether EBV-transformed cells, though not
induced to undergo isotype switching by viral infection, were still
capable of switching given signals that mimic physiologic T cell
help. CD40L and IL-4 stimulation is known to induce isotype
switching to IgG in freshly isolated N cell preparations in vitro [32–
34], with switching also to IgA in the presence of IL21 [35]. Early
passage bulk cultures (2–3 weeks post-infection) of N- and NSM-B
cell origin were exposed to these inducing signals for 10 days;
parallel cultures being maintained under normal conditions as a
control. Figure 3C shows the results from an N-derived culture,
typical of that seen generally with early passage cultures of N or
NSM origin. Untreated cultures were uniformly IgD
+ and lacked
Figure 3. Immunophenotype of LCLs derived from different B
cell subsets. (A) RT-PCR analysis of IgH gene expression. RNA from two
naive (N)-LCLs, two non-switched memory (NSM)-LCLs and one
switched memory (SM)-LCL was subjected to RT-PCR using a common
primer in IgHV and a reverse primer specific for IgM, IgD, IgG or IgA
transcripts. PCR products were analysed by agarose gel electrophoresis
and visualised by ethidium bromide staining. Also shown are results
from control IgG
+, IgA
+ and IgM
+ IgD
+ LCLs, while RNA from Jurkat cells
was included as a negative control. (B) Two colour FACS analysis of bulk
N, NSM and SM B cell-derived LCLs after dual staining cells with either
RPE-labelled anti-IgD and FITC-labelled anti-IgG Abs or RPE-labelled
anti-IgM and FITC-labelled anti-IgA Abs. (C) FACS staining of surface
IgD, IgG and IgA in a representative N-derived LCL (initially IgD
+ IgG
2
IgA
2) either untreated or exposed to CD40L/IL-4/IL21 for 7 days. Isotype
control staining is shown in black lines; IgD, IgG and IgA staining shown
in pink, green and red lines, respectively.
doi:10.1371/journal.ppat.1002697.g003
Table 1. Ig phenotype of N-, NSM- and SM-derived LCLs.
Culture
No.
tested
IgM
+
IgD
+ IgG
+ IgA
+
IgM
+
IgD
2 Mixed
N LCL, bulk 13 13 0 0 0 0
NL C L ,L D
{ clone 82 82 0 0 0 0
NSM LCL, bulk 4 4 0 0 0 0
NSM LCL, LD
{ c l o n e 88000 0
SM LCL, bulk 6 0 0 0 0 6*
SM LCL, LD
{ clone 45 0 16 23 0 6
{
{LD indicates cultures established under conditions of limiting cell numbers.
*indicates bulk LCL cultures derived from infection of switched memory (SM) B
cells and containing predominant populations of IgG
+ and IgA
+ cells with small
numbers of IgM
+ IgD
2 cells.
{indicates six LD LCLs derived from infection of SM B cell and containing both
IgG
+ and IgA
+ cells.
doi:10.1371/journal.ppat.1002697.t001
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exposed to CD40L+IL4+IL21switched to IgG or IgA, with
concomitant loss of IgD.
Ig genotype of EBV-transformed limiting dilution cultures
of N, NSM and SM origin
We now examined the Ig genotype of all LD-LCLs established
from the N, NSM and SM cell preparations whose pre-infection Ig
genotypes had been analysed in Figure 1D. For each LD-LCL, we
sequenced several cloned IgH PCR products, identified the
constituent IgH V, D and J alleles and then assigned the sequences
to individual CDR3 clones. By these criteria, the majority of LD-
LCLs (whether derived from N, NSM or SM cells) were
dominated by a single cellular clone; in addition, some were
oligoclonal with 2 or 3 different clonotypes. Individual sequences
within each identified clone were assigned as germline or mutated
as described above.
Table 2 shows results from one such experiment, here focusing
only on infections of the N cell subset. The individual clonotypes
detected within each LD culture are identified through their IgH
V, D and J alleles and their signature CDR3 amino acid sequence.
In this experiment, of 25 cultures analysed, there were 13
monoclonal cultures (LCL6-1 to 6-13) and 2 biclonal cultures
(LCL6-14, 6-15) with non-mutated genotypes. Surprisingly,
however, there were also 7 monoclonal cultures with mutated
genotypes (LCL6-16 to 6-22), plus 3 biclonal cultures (LCL6-23 to
6-25) with both mutated and non-mutated genotypes. Figure S1
presents the actual sequences for three of the above cultures;
LCL6-2, LCL6-18 and LCL6-20 with 0, 5 and 7 mutations,
respectively.
The above pattern of results, with a number of N-derived LD-
LCLs showing significant levels of IgH mutation, was observed in
8 successive experiments, each involving a different naive B cell
preparation. Combining data from all 8 experiments, we analysed
594 IgH sequences from 140 LD cultures of EBV-infected N cell
preparations, and within these identified 198 distinct clones. The
majority of these cultures (89/140) yielded only germline
sequences, usually with a single CDR3 clonotype or in some cases
with two co-resident clonotypes. However, the other 51/140 N-
derived cultures yielded mutated sequences, in most cases in the
absence of any detectable germline sequence. Overall, 72 of 198
(36.3%) individual clonotypes identified within these cultures were
Table 2. IgH genotype of LD LCL clones derived by naive B cell infection (donor 6).
LD LCL IGHV IGHD IGHJ CDR3 translation Mutations
6-1 V3-11*01 D5-24 J6*02 CAREWGGYKPLTWVDYYCGMDVW 0
6-2 V3-23*01 D6-19 J4*02 CAKDRLAVAVFWDYW 0
6-3 V4-04*02 D3-3 J3*02 CARSITIFGVVSAELDAFDIW 0
6-4 V1-08*01 D4-17 J4*02 CARGGYYEGFDYW 0
6-5 V1-69*01 D6-13 J4*02 CASASRDSSSWYERPFDYW 0
6-6 V3-48*03 D3-22 J4*02 CARDQGGVTTGAEFDYW 0
6-7 V3-23*04 D3-10 J6*03 CAKEWVGSGSYYGKPTAGYYYYMDVW 0
6-8 V4-b*01 D6-19 J4*02 CARTLVVVDW 0
6-9 V3-74*02 D3-3 J4*02 CARTRITIFGVANLDYW 0
6-10 V3-48*03 D5-5 J4*02 CARDRSRDTAMVVFDYW 0
6-11 V3-11*01 D4-17 J6*02 CARDYGDYGAWDYYYYGMDVW 0
6-12 V5-51*01 D3-10 J4*02 CARQSFGAYYFDYW 1
6-13 V4-59*01 D3-10 J4*02 CARAPAITMVRGVIEYYFDYW 2
6-14 V3-15*01 D5-12 J4*02 CTTDQWLSWEAELCW 0
V1-69*06 D6-13 J4*02 CARDSSSSWYYFDYW 1
6-15 V4-31*01 D2-21 J6*02 CARVRLAGPLARNYYYGMDVW 1
V5-51*01 D6-19 J5*02 CARHEEAGEVSWFDPW 1
6-16 V3-30*04 D4-23 J4*02 CAREATEVPFDSW 3
6-17 V4-4*02 D2-2 J4*02 CARGRFEEDYW 4
6-18 V1-58*01 D3-10 J5*02 CAVELWFGDIRWFDPW 5
6-19 V3-49*04 D1-26 J6*02 CTNSGSYYFYGVDVW 6
6-20 V4-59*01 D6-19 J4*02 CASGSSGWLYYFDYW 7
6-21 V3-48*03 D3-10 J4*02 CAVLGSEYSDEPFDYW 9
6-22 V1-3*01 D4-11 J6*02 CARDPRTVTRHSYYYYMDVW 9
6-23 V3-21*01 D5-12 J4*02 CARGDRGDTLRVMDYW 0
V3-21*01 D5-12 J4*02 CARGDRGDTLRVMDYW 3
6-24 V3-21*01 D1-26 J4*02 CAREELRGYWG 0
V1-69*01 D3-22 J4*02 CARNQDTSGSLQFDYW 3
6-25 V3-21*01 D4-17 J4*02 CARMTTVTRLVDYW 0
V3-21*01 D3-3 J6*02 CVRAPWSGDYFYYYGLDVW 5
doi:10.1371/journal.ppat.1002697.t002
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above experiments we also analysed 38 NSM-derived and 55 SM-
derived LD cultures from infections of the memory cell subsets.
Within these we identified 54 and 96 resident clones, respectively,
most cultures being dominated by a single or by two co-resident
clonotypes. Not surprisingly, given the predominance of mutated
IgH sequences present in these B cell subsets pre-infection, all of
the NSM-derived and all but two of the SM-derived cultures
carried mutated IgH sequences.
Figure 4 summarises the overall IgH genotype data from the N,
NSM and SM cell preparations pre-infection (open bars) and from
the derived LD-LCL cultures (shaded bars). The histograms show
the total number of unique clonotypes observed in relation to their
degree of divergence from germline, sequences with 0, 1 or 2
changes deemed non-mutated. Note that the degree of IgH
sequence divergence among NSM-derived and SM-derived LD-
LCLs is not markedly different from that within the matched pre-
infection populations. More importantly, however, mutated IgH
sequences are much more common in LD-LCLs derived the N cell
subset than in their pre-infection counterparts.
Characterising N-derived LD-LCLs with mutated and non-
mutated Ig genotypes
We were interested to know whether the frequent appearance of
clones with mutated Ig genotypes in LD-LCLs derived from N cell
infections reflected a growth rate advantage that these cells
enjoyed, perhaps one that might be linked to differences in the
degree to which cells were leaving the EBV-transformed latent
state and entering lytic cycle. Early passage freezings of the
emergent N-derived LCLs from individual experiments were
therefore taken from cryostorage and compared in proliferation
assays. Figure 5A shows typical results from one such experiment
comparing 5 mutated and 4 germline clones from the same donor.
The emergent LD-LCLs varied considerably in their growth rates,
but this was not related to their Ig genotype status; clones with
mutated genotypes (closed symbols) and clones with germline
genotypes (open symbols) showed a similar spread of growth rates.
Furthermore, as is clear from the immunoblots in Figure 5B,
neither Ig genotype status nor growth rate showed any obvious
correlation with expression levels of EBV latent proteins (here
illustrated using the key transformation-associated proteins
EBNA1, EBNA2 and LMP1) or with the degree of lytic cycle
entry as detected from levels of the immediate early lytic protein
BZLF1. Thus, although cells with mutated Ig genotypes are well
represented among LD-LCLs from naive cell infections, this is not
because they have an inherently faster growth rate than cells
carrying germline IgH sequences.
Ig genotype of mitogen-activated versus EBV-
transformed bulk cultures of N origin
The above evidence for mutated Ig genotypes in N-derived LCLs
came entirely from mono- or bi-clonal populations expanded from
individual limiting dilution cultures, i.e. from wells scored positive at
the end of the 6 week transformation assay. Because many such
wells still contained just small foci of transformed cells at that time,
limitations on cell numbers precluded any prospective analysis of
these cultures during their early period of expansion; as a result,
sampling of LD-LCLs for genotypic analysis was often delayed until
9–12 weeks post-infection. As a second approach therefore, we
turned to the analysis of resident clonotypes within bulk N cell
cultures, harvesting aliquots of the same culture at regular intervals
up to 12 weeks post infection. This allowed us to compare the clonal
composition within an expanding EBV-infected culture with that
seen in a matched culture driven to expand by repeated exposure to
a non-viral proliferative trigger, CD40L/IL4. In our hands, this
latter protocol induces expansions within the first 9 weeks which are
at least as the equal of those driven by EBV, after which
proliferation slows to a halt. Note that such mitogen-driven
proliferation has never been reported to induce Ig gene mutation
[36–38].
We first used the approach of IgH CDR3 spectratyping to gain
an overall picture of CDR3 length distribution (i.e. clonality) in the
two types of culture. Data from one such experiment are shown in
Figure 6A. Clearly the CD40L/IL4-activated culture remains
Figure 4. IgH mutation frequency in uninfected B cell subsets
and derived LCLs. Histograms show the number of mutations among
IgH clonotypes amplified from naı ¨ve, non-switched memory and
switched memory B cell preparations before EBV infection (open bars)
and among sequences amplified from the derived limiting dilution LCLs
(shaded bars). Mutations were only scored between IgH codons 9–92
(i.e. excluding CDR3). Where LD LCL cultures yielded multiple sequences
with differing numbers of mutation within the same CDR3 clone, the
sequence with the maximum number of mutations was scored.
doi:10.1371/journal.ppat.1002697.g004
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Gaussian distribution of CDR3 lengths to that seen in the original
starting population. In contrast, the parallel EBV-transformed
culture is dominated by sub-populations with distinct CDR3
lengths at both 6 and 9 weeks post-infection. The same samples
were analysed by IgH sequencing as before, and the corresponding
data are shown in Table 3. Thus all 18 sequences amplified from
the initial N cell population ex vivo were unique and 17/18 of these
Figure 5. Characterisation of LCL cultures derived from naive B cells. (A). Growth rate analysis of representative LD-LCLs, all derived from the
same naive B cell preparation, were measured over 7 days. LCLs with germline IgH alleles are shown by the open symbols and LCLs with mutated IgH
alleles are shown by solid symbols. (B). Immunoblots showing expression of EBV antigens EBNA1, EBNA2, LMP1 and BZLF1 in the same LD-LCLs as
shown in panel (A). Bjab was used as a EBV-negative control; X50/7 LCL was used as a positive control for EBNA1, EBNA2 and LMP1, while Akata-BL
cells induced with anti-IgG into lytic cycle were used as the control for BZLF1 expression. Calregulin was used as a loading control.
doi:10.1371/journal.ppat.1002697.g005
Figure 6. CDR3 spectratype analysis of mitogen-activated B blasts and LCL cultures derived from naive B cells. (A) Results of capillary
gel electrophoresis of IgH PCR amplification products from uninfected naı ¨ve B cells, B CD40L/IL4 stimulated naive B blasts and naive B cell-derived
LCLs established from donor 11 (tested at 6 and 9 weeks). A bell-shaped curve of PCR product peak sizes seen in the uninfected control culture and in
the naı ¨ve B blast cultures indicates a polyclonal B cell population, while the small number of distinct peaks visible in the LCL cultures indicate that the
population is dominated by a small number of clones. (B) Results of capillary gel electrophoresis of IgH PCR amplification products from naive B cell-
derived LCLs established from donor 8. While a broad distribution of CDR3 lengths is observed in the uninfected control culture and 4 week LCL, only
a small number of distinct peaks are visible in the LCL cultures at later time points indicating that the population is evolving towards monoclonality.
doi:10.1371/journal.ppat.1002697.g006
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infection (donor 11).
IgH sequence IGHV IGHD IGHJ CDR3 translation Mutations
Naive B cells
1 V3-48*01 D3-10 J6*02 CARARHRWFGENYYYYGMDVW 0
2 V5-a*01 D6-19 J4*02 CARPDPGAAASGWYNW 0
3 V3-21*01 D3-10 J6*02 CARDPTVWFGEFEQHHPYYYYGMDVW 0
4 V3-23*01 D2-15 J3*02 CAKDRGYCSGGSCRDAFDIW 0
5 V4-59*01 D3-9 J4*02 CARGGAGYFDWDGDYW 0
6 V5-51*01 D1-1 J6*02 CARHFTTGYYYGMDVW 0
7 V1-24*01 D3-16 J6*02 CATPWGWGIFGTYYGMDVW 0
8 V5-51*01 D6-6 J4*02 CARHASIVDYYFDYW 0
9 V5-51*01 D2-21 J4*02 CARAGRDDFLDYW 0
10 V3-23*04 D3-3 J4*02 CANLGAYDFWSGYYDLSTDW 0
11 V4-59*01 D3-22 J5*01 CARASSGYYRRFDYW 0
12 V4-39*01 D3-10 J4*02 CARHQDYYVCPPDYW 0
13 V3-48*02 D2-2 J6*02 CASKVVPAAIGYYGMDVW 0
14 V4-31*03 D5-12 J6*02 CARGLWWLQYYGMDVW 0
15 V3-07*03 D4-4 J6*02 CARGMTTVTGYYYYGMDVW 0
16 V3-07*03 D2-15 J6*02 CARDDAGMGCSGGSCYSVSYYYYSMDVW 0
17 V4-31*03 D4-17 J5*02 CASSSTVTMGWFDPW 1
18 V3-11*03 D6-19 J6*02 CARDLRVDSSGWKGDYYYGMDVW 4
Naive B blasts
1 V3-15*07 D2-15 J6*02 CTTEGKPVAATQWGYYYYDMDVW 0
2 V1-46*01 D1-26 J6*02 CAGSTLVGAPWDYYYGMDVW 0
3 V4-31*03 D2-21 J5*02 CARGYCGGDCYMGGPW 0
4 V3-23*01 D4-23 J4*02 CAKEEWTTVVPGVFDYW 0
5 V5-a*01 D6-19 J4*02 CARPPKNSIAVAGARDYW 0
6 V3-21*01 D5-5 J6*02 CARDRAIDTAMWDYGMDVW 0
6 V4-31*03 D1-26 J2*01 CARDGNQWETIRW 0
7 V3-53*01 D6-19 J6*02 CARAGVGHYYYYGMDVW 0
8 V1-2*02 D1-26 J5*02 CARDLEWEPRRGNWFDPW 0
9 V3-21*01 D4-17 J4*02 CARDQGDYVVWHYFDYW 0
10 V3-21*01 D3-22 J4*02 CARDPGQPKNYYDSSGASGGYW 0
11 V6-1*01 D3-3 J4*02 CASSFGVGLDYW 0
12 V4-61*01 D4-23 J5*02 CASLSITMIVAW 1
13 V3-23*01 D4-23 J4*02 CAKVGGKRITMIVVGSW 1
14 V3-15*07 D6-6 J6*02 CTRPPSGMDVW 1
15 V4-4*07 D2-15 J6*02 CVGEVVVVAATPSYYYGMDVW 1
16 V4-31*03 D5-24 J5*02 CARDGVEMATRRAPNWFDPW 1
17 V1-69*09 D6-13 J6*02 CARPPGGGARTGYYGMDVW 1
Bulk LCL derived from naive B cell infection
1 V4-31*03 D6-19 J5*02 CARVRPRIAVAGTGGWFDPW 0
2 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
3 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
4 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
5 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
6 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
7 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
8 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
9 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
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culture after 9 weeks expansion by CD40L/IL4 were unique and
non-mutated. However, the parallel EBV-transformed culture
analysed at 9 weeks contained only 5 distinct clonotypes, three of
which appeared from their frequent detection to represent
numerically dominant cell clones. Of these three dominant clones,
one (in this case, the most frequent) had a germline IgH sequence
while the other two had 3–4 mutations relative to the nearest
germline sequence.
In some experiments, greater cell yields in the N-subset sort
allowed more frequent sampling of the EBV-infected bulk cultures.
The CDR3 spectratyping data from one such experiment are
shown in Figure 6B, clearly showing that the population remains
broadly distributed in terms of CDR3 size up to 4 weeks post-
infection but becomes much more focused by 6 weeks and further
focused by 9 and 12 weeks. The corresponding IgH sequence data
from this experiment are presented in Table 4. They show that the
EBV-infected N cell culture is composed of multiple unique clones
both at 2 weeks, when all amplified sequences were germline, and
also at 4 weeks, at which point the first mutated sequences appear
as minor components. By 6 weeks, three clonotypes (one of which
was previously seen at week 4) together account for about half the
amplified sequences and by 9–12 weeks the culture is dominated
by just one of these clonotypes, with another remaining as a minor
component. In this case, the dominant IgH clonotype in the N-
derived bulk LCL is clearly mutated.
Such EBV-infected bulk cultures were generated from six
independent donors, in three cases with a matched CD40L/IL4-
stimulated B blast culture. Figure 7 presents a summary of the IgH
genotype data from the two types of cultures expressed as
histograms; the height of the open bar indicates the percentage of
sequences with a particular level of mutation frequency that were
amplified from the bulk cultures at different times, while the
shaded area of the bar reflects the proportion of those amplified
sequences that were members of a clonal family i.e. were detected
twice or more. Thus, in starting polyclonal populations, all IgH
sequences are unrelated to one another and the great majority are
non-mutated. This remains the pattern seen at all times in the
CD40L/IL4-expanded B blasts, whereas in EBV-infected cultures,
the situation changes with time post-infection. Early on these
cultures are also polyclonal and non-mutated but, at around 4
weeks post-infection, mutated IgH sequences appear in significant
numbers. From 4 to 12 weeks post-infection, the cultures then
become increasingly dominated by a small number of individual
clones; in some cases (e.g. Table 3) the most abundant clonotype is
non-mutated, while in other cases (e.g. Table 4) it is mutated,
much as seen earlier in the limiting dilution culture experiments.
Mutations within the Ig gene sequences reflect SHM
targeting
To ask whether the above Ig sequence changes seen in vitro
might be products of SHM, we first screened N, NSM and SM
Table 3. Cont.
IgH sequence IGHV IGHD IGHJ CDR3 translation Mutations
9 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
10 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
11 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
12 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
13 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
14 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
15 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
16 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
17 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
18 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
19 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
20 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
21 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
22 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
23 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
24 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 0
25 V1-58*01 D3-16 J6*02 CAADFTFGGVIASSSYYYYGMDVW 1
26 V3-7*03 D6-13 J4*02 CALRIAAAGTRALPFDYW 2
27 V3-7*03 D6-13 J4*02 CALRIAAAGTRALPFDYW 3
28 V3-7*03 D6-13 J4*02 CALRIAAAGTRALPFDYW 3
29 V3-7*03 D6-13 J4*02 CALRIAAAGTRALPFDYW 3
30 V4-4*07 D3-22 J4*02 CARASQGYDSSGYYSYFFDYW 3
31 V4-4*07 D3-22 J4*02 CARASQGYDSSGYYSYFFDYW 3
32 V4-4*07 D3-22 J4*02 CARASQGYDSSGYYSYFFDYW 3
33 V4-4*07 D3-22 J4*02 CARASQGYDSSGYYSYFFDYW 4
34 V3-30*03 D5-5 J4*02 CAKTPRVATIMYYFDYW 5
doi:10.1371/journal.ppat.1002697.t003
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IgH sequence IGHV IGHD IGHJ CDR3 translation Mutations
2 week LCL
1 V4-59*01 D3-10 J6*02 CARHSGITMVRPLDYYYYYGMDVW 0
2 V1-46*01 D3-16 J4*02 CARDGGFVGATDFDYW 0
3 V1-18*01 D3-9 J4*02 CARSTGGYDILTGYFPFDYW 0
4 V1-58*01 D2-2 J6*02 CAAQNDIVVVPAAMGIGYGMDVW 0
5 V4-61*01 D3-22 J5*02 CARYEYYYDSSGFYWFDPW 0
6 V4-59*01 D1-26 J1*01 CARETIVGATTAYFQHW 0
7 V1-69*01 D3-22 J2*01 CASSSGYPDWYFDLW 0
8 V5-a*01 D6-19 J4*02 CARLSGWYSESHYW 0
9 V3-15*07 D6-19 J4*02 CTTGIRIAVAGPSFDYW 0
10 V4-31*03 D5-5 J4*02 CARENNEGSPFDYW 0
11 V4-31*01 D4-17 J4*02 CARSPRLRGPYYFDYW 0
12 V1-18*01 D3-3 J6*02 CARGSYDFWSGYYDYGMDVW 0
13 V1-46*01 D3-22 J5*02 CVTDSSGFHWFDPW 0
14 V5-51*01 D5-5 J4*02 CARHVTAMADYW 0
15 V3-48*03 D2-2 J6*02 CARDGVPAAMGYYYYYGMDVW 0
16 V3-30*01 D3-10 J6*02 CARDPGVTYYYGMDVW 0
18 V4-31*03 D2-2 J4*02 CARQVAAAVDYW 0
19 V1-3*01 D1-1 J4*02 CARGPTDYW 0
20 V3-74*01 D2-15 J6*02 CARRGGSDIYYYYGMDVW 0
22 V3-48*03 D4-4 J6*02 CARDYSNYDYYYYYGMDVW 0
23 V3-23*01 D3-22 J4*02 CAKSSNYYDSSGYYSAW 0
25 V5-51*01 D3-10 J6*02 CARLYYGSGPWGMDVW 0
26 V3-30*03 D5-12 J6*02 CARAGTRYYYYGMDVW 0
29 V1-69*06 D3-10 J6*02 CASSNTVLGGDYYYGMDVW 0
21 V1-2*04 D3-3 J3*02 CARDGNLGRGDAFDIW 1
24 V4-59*01 D3-3 J4*02 CARSPPGLNNYFDYW 1
30 V5-51*01 D3-16 J6*02 CARLGAAMVFYYGMDVW 1
31 V4-39*01 D5-5 J5*02 CARPRHDITMIVSW 1
32 V1-24*01 D2-15 J6*02 CACCSRSEDYYYGMDVW 1
4 week LCL
1 V4-61*01 D6-6 J4*02 CARDSSAARPDYW 0
2 V4-39*01 D2-2 J3*02 CARAGGKLVAAFDIW 0
3 V4-59*01 D3-16 J5*02 CARSGQVRFGFDPW 0
4 V1-69*01 D2-21 J6*02 CARAGGRDPPYYYYYYGMDVW 0
5 V4-59*01 D3-22 J4*02 CARAVGGPPFFNSSGYPIFDYW 0
6 V5-51*01 D6-19 J4*02 CARLQDSPPDYW 0
7 V1-46*01 D5-5 J4*02 CAREAVRYSYGHDYW 0
8 V1-f*01 D3-22 J4*02 CATARSTGYLAYW 0
9 V5-51*01 D4-4 J6*02 CARYGSYPYYYYGMDVW 0
10 V4-31*03 D5-5 J4*02 CARDGYGLDYW 1
11 V3-7*03 D1-1 J3*02 CARDTNWNGAPSAFDIW 1
12 V3-21*01 D6-13 J6*02 CARDVGSSSWYNYYGLDVW 1
13 V4-39*03 D1-26 J4*02 CARAASGSLDYW 1
14 V3-30*07 D3-22 J4*02 CAKSRYYYDSSFDYW 2
15 V3-23*04 D6-19 J4*02 CARGSSGWW 2
16 V4-59*01 D3-3 J4*02 CARVRLSGWYYFDYW 3
17 V4-4*02 D1-26 J4*02 CARDQGSYYGRWIDYW 5
18 V4-b*01 D1-7 J4*02 CARVSLEAVXFDYW 5
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IgH sequence IGHV IGHD IGHJ CDR3 translation Mutations
19 V1-46*01 D6-19 J6*02 CARDSSGWYSTGYGMDVW 6
6 week LCL
1 V1-69*01 D4-23 J6*02 CARESTGDYYYYYGMDVW 0
2 V4-31*03 D5-24 J6*02 CARELKRWLQSGGGMDVW 0
3 V4-b*02 D3-22 J6*02 CARDTYYDSNGMDVW 0
4 V4-59*01 D1-26 J5*02 CARDLGSQWELGPW 0
5 V4-59*01 D1-26 J5*02 CARDLGSQWELGPW 4
6 V5-51*01 D4-23 J6*02 CARHGGGNSRYYGMDVW 0
7 V4-39*01 D4-23 J3*02 CLGGNDAFDIW 1
8 V5-51*01 D3-22 J4*02 CARQTDDSSGYYDYW 1
9 V4-59*01 D6-19 J6*02 CASMPSIAVAGDYYYYGMDVW 1
10 V3-64*05 D6-19 J6*02 CVKEGSSYYYYYYGMDVW 2
11 V3-23*04 D6-19 J4*02 CARGSSGWW 2
12 V3-23*04 D6-19 J4*02 CARGSSGWW 5
13 V3-48*02 D3-10 J6*02 CARVRGWTTYGMDVW 2
14 V3-48*02 D3-10 J6*02 CARVRGWTTYGMDVW 5
15 V3-48*02 D3-10 J6*02 CARVRGWTTYGMDVW 6
16 V3-48*02 D3-10 J6*02 CARVRGWTTYGMDVW 6
17 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 2
18 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
19 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
20 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
21 V3-23*04 D2-2 J6*02 CAKDLGYCSSTSCYADRYGMDVW 4
9/12 week LCL
1 V3-23*04 D6-19 J4*02 CARGSSGWW 2
2 V3-23*04 D6-19 J4*02 CARGSSGWW 2
3 V3-23*04 D6-19 J4*02 CARGSSGWW 3
4 V3-23*04 D3-3 J4*02 CAKGCGGVKTIGCDCW 5
5 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 4
6 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
7 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
8 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
9 V3-23*04 D3-10 J6*02 CAKGRGFGELHGMDVW 7
10 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
11 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
12 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
13 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
14 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
15 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
16 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
17 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
18 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
19 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
20 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
21 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
22 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
23 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
24 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
25 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 7
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which is essential (but itself not sufficient) for SHM to occur [39]. In
each case, AID transcription was undetectable before infection and
was activated by EBV. Figure S2A shows the relevant data from N
cell preparations. Interestingly, even though all cells in the culture
were actively infected and proliferatingby day 7 post-infection, AID
levels rose only slowly, not reaching their steady state level until day
35, kinetics that areat least compatible with the delayedappearance
of mutated IgH sequences in such cultures. However, we found no
correlation between AID expression and Ig gene mutation status.
ThusAID transcript levels weresimilar inN-derivedLCLs withand
without mutation as well as in NSM- and SM-derived lines;
interestingly these AID levels were not only lower than seen in
freshly-isolated GC B cells and in 4 Burkitt lymphoma (BL)-derived
cell lines, included as SHM-positive controls, but also much lower
than those in CD40L/IL4-stimulated B blasts which lack detectable
SHM (Figure S2B,C). Moreover N-derived LCLs with and without
IgH mutations gave similar results in quantitative RT-PCR assays
specific for alternatively-spliced AID mRNAs and for the Polg and
UNG co-factors involved in the SHM process [40,41] (Figure S2C).
As a second approach, we asked whether the IgH gene
mutations seen in N-derived LCLs had the hallmark of SHM
targeting by mapping the location of all IgHV sequence changes
seen in pre-infection N, NSM and SM populations and in their
derived LCLs. To avoid distortion of the LCL data by numerically
dominant clones, here any one mutated clonotypic sequence
identified within an LCL only contributes once to the cumulative
data. The overall findings are summarised in Figure 8, where the
height of the bars indicates the number of times a change in a
particular IgHV codon was identified. Sites in the IgHV sequence
known to be favoured by the SHM machinery (hot-spots) [42,43]
are identified by filled bars. Focusing first on the data from pre-
infection B cell subsets, as already described we found very few
mutations in the N-subset, while the NSM and SM subsets showed
the expected distribution of mutated sites, with frequent
involvement of known SHM hotspots and avoidance of coldspots.
Not surprisingly, the NSM- and SM-derived LCLs showed a
similar distribution of mutations as in their pre-infection
populations. However, it was striking that the same pattern of
distribution was also seen among the mutated IgH clonotypes
found in N-derived LCLs, at least consistent with these changes
being a product of SHM.
Such findings nevertheless leave open the possibility that the
mutated clonotypes frequently detected in N-derived LCLs have
not arisen from authentic naive cells induced into SHM in vitro
but from memory cells already carrying IgH mutations that were
present as minor contaminants of the original N cell preparations.
Note that the transformation assays on sorted B cell subsets
(Figure 2) implied that memory cell contaminants would enjoy no
competitive advantage in such a situation. Furthermore, the IgM
+
IgD
+ phenotype of the mutated LCLs discounted their being
derived from isotype-switched SM cells. However we could not
formally discount a contribution from NSM contaminants from
the Ig phenotype since both N-derived and NSM-derived
transformants would give the same IgM
+ IgD
+ LCL signature.
The possibility of resolving this issue by genotype was raised by a
recent report [44] that a proportion of NSM cells carry mutations
in the Bcl6 intronic major mutation cluster (MMC), mutations that
(as in conventional memory cells) are thought to arise through
SHM mis-targeting during a cell’s residence in GCs where Bcl6 is
highly expressed [44,45]. If such mis-targeting is indeed dependent
upon active bcl6 transcription, then this would not be expected to
occur during EBV-induced B cell transformation in vitro because,
as already reported [46] and as we confirmed in the present work
(Figure S3), Bcl6 expression is suppressed by growth-transforming
EBV infection. We therefore selected 18 LD-LCLs that had a
mutated Ig genotype and were derived from N cell preparations,
amplified a 718bp region of the Bcl6 MMC, then cloned and
sequenced multiple independent amplification products. As
internal controls, we included parallel amplifications from sorted
naive and memory B cell populations ex vivo. As shown in Table
S1, 17/18 Bcl6 MMC sequences amplified from naive B cells were
germline, whereas 10/24 sequences from memory cells were
mutated; such findings are in close accord with an earlier report
[44]. Turning to the Ig-mutated LD-LCLs from N cell infections,
we detected both germline and mutated allelic sequences in just 2
lines; the great majority of lines (16/18) only ever yielded germline
sequences. Overall, therefore, the bcl6 data are again consistent
with the majority of these Ig-mutated LD-LCLs being truly
derived from naive cells.
Intra-clonal diversification of Ig sequences in EBV-
transformed bulk cultures of N subset-origin
To pursue the question another way, we reasoned that if the
mutated clonotypes arising in EBV-infected N cell cultures were
truly being generated from naive precursors in vitro, then we should
be able to detect evidence of intra-clonal sequence diversification
within such cultures. In this regard, 28 of the 72 LD-LCLs in which
the dominant clonotypic sequence was mutated also contained
variants (typically with1 to3 nucleotide changes) ofthat sequenceat
the single point of harvesting. More informative, however, are the
data from bulk N-cell infections sampled over time. Summing data
from all 6 experiments, each involving a different N-cell donor, we
identified a total of 17 mutated clonotypes that were present on two
or more occasions in the same culture between 4 and 12 weeks post-
infection; of these, 14/17 clonotypes showed evidence of intra-
clonal sequence variation, with a total range of 1–12 sequence
changes per clonotype. Two such examples are presented in
Figure 9, where in each case the variants can be linked into family
Table 4. Cont.
IgH sequence IGHV IGHD IGHJ CDR3 translation Mutations
26 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 8
27 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 8
28 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 8
29 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 8
30 V3-23*04 D3-10 J6*02 CAKDRGFGELHGMDVW 8
31 V3-23*04 D2-2 J6*02 CAKDLGYCSSTSCYADRYGMDVW 7
doi:10.1371/journal.ppat.1002697.t004
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parental sequence. In one case (Figure 9A), we found the parental
IgH sequence and 9 clonally-related variants with up to 8 sequence
changes; in another case (Figure 9B and Table 4), we found the
parental IgH sequence and a further 5 related variants with up to 6
sequence changes. The detailed sequences used to construct these
trees are shown in Figures S4A and S4B.
Discussion
As originally stated, the different views as to how EBV
selectively colonises the SM B cell subset in vivo hinged on whether
this was GC-dependent, involving preferential infection of naı ¨ve
cells that the virus then induced into memory via GC transit [1],
or GC-independent, involving preferential infection/expansion of
pre-existing memory cells [2]. Neither view can fully accommo-
date the more recent finding that EBV also colonises the IgD+
CD27+ NSM subset, not just in healthy carriers [21] but also in
patients congenitally devoid of GCs and therefore of SM cells; in
such patients the NSM subset is hugely outnumbered by naı ¨ve B
cells (and is therefore very unlikely to be a preferential target of
primary infection) yet it harbours essentially all the latent virus
[29]. Given the difficulties posed by such in vivo findings, the
present work took the reductionist approach of focusing on
experimental infection of N, NSM and SM cells in vitro. This
showed that, while EBV itself does not induce Ig isotype switching,
N-derived LCLs remain susceptible to switching induced by
surrogate T cell signals. More importantly, in at least a proportion
of N cells, EBV infection induces IgH sequence changes which
bear the hallmarks of SHM; furthermore, B cell clones with such
changes frequently become numerically dominant as the emerging
LCL evolves towards monoclonality, typically beginning between
4–6 weeks post-infection. These findings not only suggest
alternative routes whereby EBV might become embedded in B
cell memory in vivo but also strengthen the argument that EBV-
induced SHM could contribute to clonal evolution in EBV-
associated lymphoproliferative lesions/lymphoma.
It was first necessary to check the susceptibility of the different B
cell subsets to EBV infection/transformation. This has been a
surprisingly neglected issue after an early study, examining B cell
subsets within EBV-infected tonsillar B cell cultures up to 48 hr
post-infection, found no differences in the infectability of cells with
different surface Ig isotypes [47]. More recently, Dorner et al. also
reported that naı ¨ve (CD27
2) and total memory (CD27
+) B cells
from tonsils were equally infectable in short-term assays, although
subsequently naı ¨ve cells grew slightly quicker and gave slightly
better LCL yields from limiting dilution seedings [48]. While naı ¨ve
(CD27
2) cells from peripheral blood resembled their tonsillar
counterparts, they were more infectable than peripheral blood
memory (CD27
+) preparations; this could not be explained at the
level of receptor (CD21)/co-receptor (HLAII) expression but was
ascribed to heterogeneity among circulating memory cells in
expression of another putative co-receptor, a5b1 integrin [49].
Comparisons with the present work are difficult because Dorner et
al. employed an unusual recombinant EBV strain (lacking one of
the latent proteins, LMP2A) whose low titre preparations
necessitated the use of spinoculation to achieve measurable rates
of infection. The present work, using wild-type EBV and
conventional infection protocols, did not detect any significant
difference in virus binding, infectability or transformability under
limiting conditions between peripheral blood N, NSM and SM
preparations (Figure 2). Likewise, another recent report comparing
naı ¨ve (CD27
2) and total memory (CD27
+) B cells from blood also
found no significant difference in transformability [50]. Interest-
ingly we noticed that, in contrast to the ease with which LCLs
grow out from positive wells at the high end of transformation
assays, only a subset of positive wells arising under limiting
conditions could be expanded to establish LCLs. This likely
reflects the fact, recently noted by others [51,52] and also apparent
from our CDR3 spectratyping of EBV-infected bulk cultures
(Figure 6), that the process of LCL establishment is associated with
significant clonal selection, a hurdle which cultures with small seed
populations may fail to overcome. The basis of this selection
remains to be determined. However, from the point of view of the
present work, we can conclude that N, NSM and SM populations
show similar levels of attrition at this stage.
Figure 7. Summary of IgH mutation frequency in mitogen-
activated B blasts and LCLs derived from naı ¨ve B cells.
Histograms show the number of mutations in IgH sequences amplified
from CD40L/IL4-stimulated B blasts and EBV-infected LCLs derived from
naı ¨ve B cell preparations at 0, 4, 6 and 12 week time points. The height
of the open bars indicate the percentage of total IgH sequences
analysed with a particular frequency of mutations, while the shaded
bars indicate the proportion of these IgH sequences detected more
than once in each culture i.e. belonging to a CDR3-related clonal family.
nt: not tested.
doi:10.1371/journal.ppat.1002697.g007
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many have observed [52–56], EBV-transformed LCLs converge
on a similar ‘‘lymphoblastoid’’ phenotype, irrespective of the
precise differentiation stage of the target B cell; importantly, that
phenotype includes the memory marker CD27, which is induced
on N-derived LCLs to levels similar to those retained on memory
LCLs [31]. By contrast, EBV transformation does not lead to
convergence of Ig isotype expression. Thus we detected no Ig
isotype switching in N- or NSM-derived LCLs, whether analysed
by transcript-specific RT/PCR assay or by protein expression
(Figure 3A, B and Table 1). This accords with early work on the
IgM
+ IgD
+ cell fraction from peripheral blood where EBV
infection induced IgM but not IgG or IgA production [57].
However it apparently contradicts another study [58] in which
switch circles, considered an early marker of class switching, and
some switch transcripts were detected in naı ¨ve B cells after EBV
infection in vitro. In that same study, however, evidence of isotype
switching at the protein level was only given for clones of the EBV-
Figure 8. Distribution of IgVH mutations in uninfected B cell subsets and derived LCLs. Histograms show the cumulative pattern of IgVH
somatic mutations in naive (N), non-switched memory (NSM) and switched memory (SM) B cell subsets pre-infection and in their derived LCLs.
Mutations were scored between codons 9–92 (according to the Kabat numbering system) with codons known to be SHM hotspots shown as filled
bars Note that each mutated clonotypic sequence identified within an LCL only contributes once to the overall data.
doi:10.1371/journal.ppat.1002697.g008
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LMP1 [58], the EBV latent cycle protein that mimics many of the
effects of CD40 ligation [59,60]. Likewise another study [61]
linking EBV with the induction of switch recombinase activity was
based on viral infection of a B lymphoma line BJAB or on EBV-
positive BL cells. In neither study, therefore, was there definitive
evidence of EBV-induced isotype switching in the setting of
normal B cells; indeed others have used EBV-infected B cells as
isotype-stable substrates in order to study switching induced by
exposure to cytokines and/or CD40 ligation [62,63]. We indeed
confirmed that EBV transformation still leaves early passage N-
and NSM-derived LCLs responsive to exogenous signals, CD40L/
IL4/IL21, that mimic T cell-derived switch signals in vivo
(Figure 3C). Thus EBV infection itself can induce naı ¨ve B cells
to acquire an NSM-like surface phenotype (IgD
+ CD27
+) and,
with appropriate T cell help, a SM-like phenotype (IgD
2 CD27
+).
Key findings arose when the study turned to virus-induced
changes Ig genotype. In limiting dilution seeding experiments,
designed to generate transformed populations of limited clonality,
we were surprised to find that .30% N-derived LD-LCLs
contained mutated IgH sequences, a result seen consistently
across experiments on 8 different B cell donors (Figure 4).
Combining data from all these mutated clonotypes gives a mean of
9.2 nucleotide substitutions per IgH sequence, a value substantially
higher than the background that would expected from PCR
amplification error and in stark contrast to the mean values of 0.4
substitutions per sequence seen in the original N cell-sorts and of
0.5 substitutions per sequence seen in CD40L/IL4-expanded N
cell cultures. Interestingly the 9.2 value is below the mean number
of mutations (15.2) we observed in SM cell preparations but
similar to the mean (7.2) seen in NSM cells and their derived
LCLs. This similarity, and the fact that all N-derived transfor-
mants were IgM+ IgD+, meant that if such mutated clonotypes
were arising from pre-existing memory cells in the original N cell
sorts, then the source of contamination must be NSM cells.
However, such a possibility seems at odds both with the high
purity of N cell preparations, shown to be .99% by IgD/CD27
staining and 97% by Ig gene sequencing (Figure 1), and with the
fact that NSM cells were not more transformable than N cells
when compared in parallel assays (Figure 2) nor more likely to
survive the clonal selection that then occurs with transition from
transformed cell focus to established LCL. Having said that, we
cannot entirely discount the possibility that some of these mutated
clonotypes derive from NSM cells contaminating the N cell sorts,
particularly in the rare cases of clones that also carry bcl6
mutations. Were NSM cells to be the source of even a small
fraction of the Ig-mutated LCLs detected in the present work, this
would be worthy of further attention since it implies that NSM-
Figure 9. Presumed genealogical trees showing examples of sequence divergence within CDR3-related clones. Each tree is based on
clonally-related IgH sequences amplified at different time points from an independent bulk LCL culture derived from EBV-infected naı ¨ve B cells. In
each case, functional IgH sequences were first aligned with the nearest germline IGH V, D and J alleles to determine the number and location of
mutations. Each clonally-related IgH sequence is represented as a box, with the number of incremental mutations shown on each branch; the
sequence name and the position of the codon changes (according to the Kabat numbering system) are indicated inside the box while newly acquired
mutations are underlined. (A) Prospective analysis of LCL5 identified a sequence (clone w4s6) with zero mutations relative to the nearest germline
allele IGHV4-59*01 and a further 9 clonally-related variants (with up to 8 additional changes) which segregated into two major branches. Note that
the same mutation at codon 70 was seen in both branch 1 and branch 2 and was therefore assumed to have occurred twice independently. (B) Serial
analysis of LCL8 identified a sequence (w6s17) with two mutations relative to the nearest germline allele IGHV3-23*04 and a further 5 clonally-related
variants with up to 6 additional sequence changes (note the change in codon 31 involved two substitutions). In this case the nearest germline IGVH
allele was a presumed hypothetical intermediate and is therefore represented as a dotted box.
doi:10.1371/journal.ppat.1002697.g009
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naive cells that is only apparent when the two are competing in
mixed culture.
However we would argue that this is not the main explanation
for our findings. Rather, the evidence suggests that many of the
mutated IgH clonotypes seen in LCLs derived from N cell
preparations have arisen in vitro from naı ¨ve precursor cells. This
rests on the observation of ongoing intra-clonal diversification
within a culture. Early in the work we noted that clonotypic
sequences varying by 1–3 nucleotides could be amplified from
some LD-LCLs, but such examples, coming from single harvests
made up to 12 weeks post-infection, are difficult to interpret in
isolation. We therefore set up EBV-infected bulk N cell cultures
that could be harvested prospectively, with parallel cultures of
CD40L/IL4-stimulated N cell blasts as controls. Such experi-
ments, carried out on N cell preparations from 6 different donors,
led to the following conclusions. Firstly, the EBV-infected
populations remain polyclonal for 4 weeks but thereafter move
quite rapidly to oligo- or mono-clonality (N.B. a previous CDR3
spectratyping study also reported clonal dominance within 12
weeks [52]); by contrast parallel cultures of CD40L/IL4-
stimulated blasts remain entirely polyclonal despite extensive
proliferation (Figure 6, Tables 3, 4). Secondly, mutated IgH
genotypes regularly appear in EBV-infected N cell cultures (but
only rarely in the CD40L/IL4 cultures) and, in 5 of 6 experiments,
grew out to become either the dominant or significant sub-
dominant clones. Thirdly, and most importantly, in some cases
family trees could be drawn tracing intra-clonal diversification
with time in the emerging LCL (Figure 9). To date, almost all
other reports of intra-clonal diversification in an LCL have come
from one late passage, monoclonal antibody-producing line
studied long after its establishment [64–66]; interestingly, however,
a recent study [31] found that 1 of 3 naı ¨ve B cell-derived limiting
dilution LCLs (included as controls in a study of GC cell
transformants) showed significant levels of IgH gene diversifica-
tion, a result which here we show to be representative of a general
trend.
It is striking that the IgH mutations observed in this study are
frequently situated at known hotspots of SHM targeting (Figure 8).
This, and the known ability of EBV to induce AID and other
factors involved in the SHM process [58,64,67], leads us to suggest
that the changes are indeed AID-mediated. However we cannot
say why EBV-induced, AID-driven IgH gene mutation was
detected in only a proportion of N-derived LCLs in these
experiments, when the expression of AID and related co-factors
UNG and DNA polg was equally well induced in all lines (Figure
S2). Mutation may be a stochastic event or possibly dependent on
the cellular context, i.e. there may be differences among naı ¨ve B
cells in their inducibility to IgH gene mutation, just as naive
populations are heterogeneous in their response to isotype-switch
signals in vitro [35].
These findings potentially bear upon two key aspects of EBV
biology in vivo. The first concerns the means whereby the virus
sequesters in memory B cell populations. It is clear from Ig
genotyping of infected cells both in the transient lymphoprolifer-
ations seen during primary infection in IM tonsils [6] and in the
progressive lymphoproliferative lesions arising in acutely immu-
nosuppressed transplant recipients [10], that at least some naive B
cells do become infected in vivo. Hence the subsequent absence of
the virus from naive populations in the immunocompetent host
must reflect either clearance of these EBV-infected naive B cells by
the T cell response (which could happen were they unable to make
the transition to an antigen-negative resting state) or the cell’s
acquisition of a memory Ig genotype/phenotype. Our data raise
the possibility that EBV infection per se could induce an NSM Ig
genotype/phenotype without germinal centre transit, while T cell
signals, perhaps in the extra-follicular environment [5,21] could
induce switching to SM status.
The second aspect of EBV biology touched on by this work
concerns the mechanisms whereby virus infection contributes to B-
lymphomagenesis. It is increasingly clear that the relatively low
efficiency with which a B cell, driven into the first cell cycle by EBV
infection, achieves outgrowth to an LCL (1–10% by some
calculations [68]), cannot be fully ascribed to the inherent limitations
of in vitro culture. Successful outgrowth reportedly requires escape
from the oncogenic stress and attendant DNA damage response to
which hyper-proliferating cells are subject within the first week (i.e.
first 5–6 divisions) post-infection [69] and also survival through a
transient period of genetic instability peaking around 4 weeks post-
infection [51]. It remains to be seen to what extent virus-driven
SHM activation contributes to these phenomena. However our
findings on clonal evolution in N cell cultures from 4–8 weeks post-
infection would suggest that naive cells in which SHM has targeted
the Ig locus have a competitive edge in outgrowth to form an LCL.
One attractive possibility is that the competitive advantage comes
not from Ig mutation per se, but from mutations in other growth/
survival-promoting genes that are coincidentally targeted by the
SHM machinery. If sucha mechanism,thought tobeinvolvedinthe
genesis of many lymphomas of GC/post-GC origin [70–72] plays
some role in determining clonal selection during LCL outgrowth,
then it represents a second way, in addition to expression of EBV’s
growth-transforming latent genes, whereby the virus may contribute
to lymphomagenesis.
Materials and Methods
Ethics statement
These studies were approved by the University of Birmingham
and the South Birmingham Research Ethics Committee, UK (07/
H/1207/271). All blood donors provided written informed
consent.
B cell isolation and purification of B cell subsets
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-Isopaque density centrifugation of adult buffy coat samples
(National Blood Service, UK) and B cells positively selected by
immunomagnetic cell isolation using CD19 Pan B Dynabeads
(Life Technologies) followed by bead detachment. B cell purity was
assessed by staining with PE-Cy5-conjugated mouse anti-human
CD20 (1:40, Dako) monoclonal antibody (mAb) and FACS
analysis on a Coulter Epics XL-MCL flow cytometer. To isolate
B cell subsets, purified B cells were co-stained with FITC-labelled
anti-IgD (1:40, Dako) and PE-labelled anti-CD27 (1:20, BD
Pharmingen) antibodies (Abs). IgD
+ CD27
2 (naı ¨ve), IgD
2 CD27
+
(switched memory) and IgD
+ CD27
+ (non-switched memory) B
cell subsets were simultaneously collected during a single FACS
sorting procedure on a MoFlo sorter (Beckman Coulter). Small
aliquots of sorted cells were used to re-analyse purity of subsets
thus isolated.
Virus binding assays
Expression of the EBV receptor, CD21 [73,74], was assessed by
FACS analysis after staining B cells and subsets with PE-Cy5
mouse anti-human CD21 mAb (1:40, BD Pharmingen). For virus
binding assays, 2610
5 B cells from each subset were incubated
with B95.8 strain EBV at 100 moi (100 EBV genome copies/cell)
for 3 hours at 4uC and the number of cell-bound virus genomes
determined by real time quantitative PCR as described [75].
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The transformation efficiency of different B cell subsets was
assayed by two different experimental assays. In one assay, 1610
6
N, NSM and SM B cells were exposed to a standard virus dose (50
moi) for 1 hour at 37uC before seeding at two-fold limiting dilutions
(from 1000 cells/well) into replicate wells of a 96-well plate
containinghumanfibroblastfeedercells.Inthesecondassay,2610
5
N and NSM cells were exposed for 1 hour at 37uC to two-fold virus
dilutions (from 50 moi) before seeding 1000 cells into replicate wells
of a 96-well plate containing human fibroblast feeder cells. In both
cases, cultures were maintained in RPMI 1640 medium supple-
mented with 2 mM glutamine and 10% v/v FCS for 6 weeks at
which time wells with typical foci of EBV-transformed lymphoblas-
toid cells were scored positive. At that time, all positive cultures at
the end-point of the titration (i.e. conditions where only a fraction of
replicate wells had transformed) were split, initially into duplicate
microtest wells, then the duplicates pooled into a 1 ml well and
thence into a 5 ml culture, in order to establish limiting dilution
(LD) LCLs for analysis. The proportion of cultures which could be
successfully expanded in this way over the following 4–6 weeks was
recorded; as an internal control, when positive cultures from the
high end of the titration (i.e. conditions giving 100% positive wells)
werelikewise treated, all could be successfully expanded to LCLs. In
other experiments, bulk LCLs of N, NSM and SM origin were
generated byinfecting2610
6 cellsofeachtype witha standardvirus
dose (50 moi), seeding into 2 ml wells and then expanding into a
25 ml flask; flask cultures were then maintained in exponential
growth by passaging twice weekly.
Generation of mitogen-activated B blasts
Activated B blasts were generated by culturing naive B cell
preparations with irradiated CD40L-expressing mouse L cells in
the presence of IL-4 [76]. Irradiated L cells were added to 24-well
tissue culture plates (0.2610
6 cell/well) and allowed to adhere over
night before the addition of 0.5610
6 B cells in 3 ml CD40L blast
medium (Iscove’s Medium supplemented with 10% human serum
and 50 ng/ml IL-4) . Cultures were passaged onto fresh L cells
twice weekly and maintained for up to 12 weeks.
Cytokine stimulation of Ig isotype class switching
Ig isotype switching was induced by culturing N and NSM B
cell-derived LCLs with irradiated CD40L-expressing mouse L cells
in the presence of IL4 and IL21 [35]. Irradiated L cells were
added to 12-well tissue culture plates (0.2610
6 cell/well) per well
prior to the addition of 2610
6 LCL cells in 1.5 ml CD40L blast
medium supplemented with 50 ng/ml IL-4 and 50 ng/ml IL21.
The cells were split after 3–4 days in culture, and harvested after 7
days for Ig staining.
Antibody staining for surface markers and Ig isotypes
LCLs were stained with fluorochrome-labelled mAbs against
CD23 (Immunotech) and CD27 (BD Pharmingen) to determine
the expression of these surface markers. Cells were also analysed
for surface Ig by staining with fluorochrome-labelled isotype-
specific mAbs to IgD, IgM, IgG and IgA (Dako). All mAbs were
used at 1:20 and staining analysed using a Coulter Epics XL-MCL
flow cytometer and WinMDI software.
RT/PCR assay for Ig isotype-specific transcripts
Total RNA was extracted from 2610
6 cells using a Nucleospin
II RNA isolation kit (Macherey Nagel) and cDNA was synthesised
using random hexamers and AMV-RT (Roche). Ig heavy chain
(IgH) sequences were PCR-amplified using a single consensus
forward primer FR1c within framework region (FR)1 [77] and one
of four IgH constant region reverse primers specific for IgM, IgD,
IgG or IgA [78]. Each PCR amplification contained 0.8 mM FR1c
primer, 0.8 mM IgH family-specific reverse primer, 200 mM
dNTPs, 1.5 mM MgCl2 and 5units Red Hot DNA Polymerase
(ABgene). The first PCR cycle consisted of a denaturing step of
94uC for 5 mins, followed by 35 cycles of denaturation at 94uC for
30 s, annealing at 61uC for 60 s and extension at 72uC for 60 s
(10 mins in the last cycle). PCR products were run on a 1.5%
agarose gel and IgH products (600 bp) identified by ethidium
bromide staining.
PCR amplification and analysis of IgH sequences
DNA was extracted from up to 2610
6 cells using a DNeasy
Tissue kit (Qiagen). Ig heavy chain variable (IgHV) sequences
spanning FR1, CDR1, FR2, CDR2, FR3, and CDR3 were PCR-
amplified using a single consensus forward primer FR1c
59AGGTGCAGCTGSWGSAGTCDGG39 and a mixture of JH
family-specific reverse primers JH1/2/4/5 59ACCTGAGGA-
GACGGTGACCAGGGT39, JH3 59TACCTGAAGAGACGG-
TGACCATTGT39 and JH6 59ACCTGAGGAGACGGTGA-
CCGTGGT39 described previously [10,77]. PCR amplification
was performed using the Expand High Fidelity PCR system
(Roche) in a reaction containing 1 mg heat denatured genomic
DNA, 0.8 mM FR1c primer, 0.26 mM each JH primer, 200 mM
each dNTP, 1.5 mM MgCl2 and 3.5units Expand High Fidelity
DNA polymerase. The first PCR cycle consisted of a denaturing
step of 94uC for 5 mins, followed by 30 cycles of denaturation at
94uC for 30 s, annealing at 61uC for 60 s and extension at 72uC
for 60 s (10 mins in the last cycle). PCR products were then
separated by electrophoresis on a 8% polyacrylamide gel, and
bands corresponding to the approximately 350 bp IgH products
excised and the DNA eluted. Finally each purified PCR product
was cloned using the pGEM-T Easy Vector System (Promega),
and following bacterial transformation, 3–5 independent bacterial
clones were subjected to DNA sequencing on a Applied Bio-
systems ABI3730 DNA analyser (Functional Genomics, University
of Birmingham).
IgH sequences were analysed using the V-Quest (http://www.
imgt.org) [79] and VBase (http://vbase.mrc-cpe.cam.ac.uk) direc-
tories to identify the nearest IGHV, IGHD and IGHJ germline
alleles; at this point sequences carrying out-of-frame CDR3
junction regions or chimaeric sequences generated by PCR
crossover between two different IgH alleles were discarded from
the analysis. Translated CDR3 junction sequences were generated
using V-Quest. IgH sequences carrying the same IGHV allele and
identical translated CDR3 sequences were assigned to the same
CDR3 clone. IgH sequences with 0, 1 or 2 nucleotide changes in
the IGHV region (between codons 9–92, based on the Kabat
numbering system [80]) were considered to be naive, and those
showing more than 2 nucleotide changes were considered to be
mutated [10]. Sequence alignments were generated and visualised
using BioEdit (http://www.mbio.ncsu.edu/bioedit/bioedit.html).
Taqman RT-PCR assay for AID transcripts
Total RNA isolation and cDNA synthesis reactions were carried
out as described above. AID, uracil N-glycosylase (UNG) and
DNA polymerase g transcripts were quantified by real time PCR
on an ABI Prism 7500 Sequence Detection System using
commercially available reagents (Applied Biosystems). Values
were normalised against GAPDH mRNA levels in the same cells
and then expressed relative to that seen in a reference AID-
positive B cell line, Ramos-BL [81]. A primer/probe combination
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designed using Primer Express software (Applied Biosystems).
Immunoblotting
Western blotting was carried out as described previously [82]
using mAbs to: EBNA1 (1H4), EBNA2 (PE2), LMP1 (CS1-4),
BZLF1 (BZ-1). Bcl6 was detected using a rabbit polyclonal Ab
(N3, Santa Cruz).
Bcl6 mutation analysis
A 765 bp fragment of the Bcl6 MMC was PCR-amplified with
the primers 59 CAAATGCTTTGGCTCCAAGTTTTCT 39 and
59 AGGAAGATCACGGCTCTGAAAGG 39 PCR amplification
using the Expand High Fidelity PCR system (Roche) in a reaction
containing 1 mg heat denatured genomic DNA, 1 mM each
primer, 200 mM each dNTP, 1.5 mM MgCl2 and 3.5 units
Expand High Fidelity DNA polymerase. The first PCR cycle
consisted of a denaturing step of 94uC for 5 mins, followed by 40
cycles of denaturation at 94uC for 30 s, annealing at 60uC for 60 s
and extension at 72uC for 60 s (10 mins in the last cycle). PCR
products were then separated by electrophoresis on a 1.5%
agarose gel, the appropriate bands excised and the DNA eluted.
Purified PCR products were cloned using the pGEM-T Easy
Vector System (Promega), and following bacterial transformation,
3–5 independent bacterial clones were subjected to DNA
sequencing. A 716 bp region of each amplified Bcl6 sequence
was aligned to a Bcl6 reference sequence using BioEdit.
Supporting Information
Figure S1 IgH sequences from 3 limiting dilution LCLs
established from LCL6. In each case the amplified IgH
sequence is aligned with the nearest germline IGHV, IGHD and
IGHJ alleles, with sequence identities shown as dots. (A) shows an
example of a germline IgH sequence while (B) and (C) show
examples of mutated IgH sequences with 5 and 7 changes,
respectively, taken from Table 2. Complementarity determining
regions CDR1, CDR2 and CDR3 are shaded. Note that the IgVH
sequence starts at codon 9 and nucleotide changes in CDR3 are
ignored.
(TIF)
Figure S2 Expression of AID and accessory factors
involved in SHM. (A) AID expression was quantified by real
time RT-PCR in a bulk LCL culture at various time points post
infection. Normalised AID values are expressed relative to the
reference BL line Ramos. (B) AID expression quantified by real
time RT-PCR in uninfected naı ¨ve (N), non-switched memory
(NSM) and switched memory (SM) B cells and N-, NSM- and SM-
derived limiting dilution LCLs. Data are shown separately for N-
derived LCLs with germline or mutated IgH sequences. Two T
cell lines (Jurkat and Molt4) and two pre-B cell lines (Nalm6 and
Nalm16) were included as negative controls, while four BL lines
(Akata-BL, P3HR1-BL, Rael-BL and Ramos-BL) and two
germinal centre (GC) B cell preparations served as positive
controls. Note that the reference Ramos-BL cell line has the lowest
AID expression of the four BL lines. AID values are expressed as
in panel A. (C) Expression of full length (FL) AID transcripts,
exon4-deleted AID variant transcripts, UNG transcripts and DNA
polg transcripts measured by real time RT-PCR. Data are shown
from 5 representative naive B cell-derived limiting dilution LCL
cultures with either germline or mutated IgH genotypes and 2
polyclonal CD40L/IL4 stimulated N cell-derived B blasts (Blast 1
and Blast 2) from separate donors. Normalised values are
expressed relative to Ramos-BL (AID) or Jurkat cells (UNG and
DNA polg). Data are the mean (+/2 SD) of triplicate readings.
(TIF)
Figure S3 Bcl6 expression is downregulated following
EBV transformation. Immunoblots show expression of Bcl6 in
representative LD-LCL cultures carrying either germline or
mutated IgH genotypes. Two EBV-positive BL cell lines (Wan-
BL, Rael-BL) were included as positive controls for Bcl6
expression. Calregulin was used as a loading control.
(TIF)
Figure S4 Examples of clonal variation within LCL bulk
cultures. Shown are selected clonally-related IgH sequences
amplified from naive B cell derived bulk LCL cultures which were
used to construct the genealogical trees shown in Figure 8. The
sequence name reflects the time post infection (in weeks, w) at
which the clone was isolated and the sequence number (s), while
the number in parentheses indicates the number of mutations
relative to the nearest germline sequence shown on the top line.
Sequence identities are shown as dots; complementarity deter-
mining regions CDR1, CDR2 and CDR3 are shaded. (A) shows
the results for LCL5 while (B) shows the results for LCL8.
(TIF)
Table S1 Bcl6 MMC mutation status in naive B cell-
derived LD LCL clones with mutated IgH genotypes.
(DOC)
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